Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.46 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944447 | 1.00 | LNPEP (0.46) | LNPEPGPR88MAPK8MAPK9KDM4E | |
| SCHEMBL22582962 | 0.79 | ALDH1A1 (0.40) | ALDH1A1MYCKDR | |
| SCHEMBL10992349 | 0.77 | KDM4E (0.51) | KDM4EHPGDALDH1A1HTTL3MBTL1 | |
| SCHEMBL19076070 | 0.76 | LNPEP (0.57) | LNPEPGPR88KDM4E | |
| SCHEMBL21944961 | 0.76 | LNPEP (0.57) | LNPEPGPR88KDM4E | |
| SCHEMBL27687851 | 0.74 | CA2 (0.41) | KDM4EALDH1A1HTTL3MBTL1MAPT | |
| SCHEMBL19999906 | 0.74 | NQO1 (0.46) | KDM4EHPGDALDH1A1MAPTGAA | |
| SCHEMBL7694741 | 0.74 | APLNR (0.35) | KDM4EHPGDALDH1A1HTTL3MBTL1 | |
| SCHEMBL28282698 | 0.73 | LNPEP (0.47) | LNPEPKDM4EALDH1A1SLC2A1MAPT | |
| SCHEMBL13570889 | 0.73 | MAOA (0.45) | KDM4EHPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975091-B2 | Pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2021-04-13 | — | — | US | disclosed |
| US-20200055868-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-10421762-B2 | Pyridine derivative | ASTELLAS PHARMA INC. (JP) | 2019-09-24 | — | — | US | disclosed |
| US-20170190715-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055868-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | LNPEP 5/4885GPR88 2104/4885MAPK8 4593/4885 |
| US-10975091-B2 | Pyridine derivative | LAP3, PREP, DNPEP | LNPEP 5/4885GPR88 2104/4885MAPK8 4593/4885 |
| US-10421762-B2 | Pyridine derivative | LAP3, PREP, DNPEP | LNPEP 5/4885GPR88 2104/4885MAPK8 4593/4885 |
| US-20170190715-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | LNPEP 5/4885GPR88 2104/4885MAPK8 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.